New learning discoveries about 137848-29-4

137848-29-4, The synthetic route of 137848-29-4 has been constantly updated, and we look forward to future research findings.

137848-29-4, (S)-2′-Amino-[1,1′-binaphthalen]-2-ol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

3,5-Di-tert-butylsalicylaldehyde (2.35 g, 10.0 mmol) was mixed with (S)-2-amino-2′-hydroxy-1,1′-binaphthyl (2.85 g, 10.0 mmol) in dry toluene (30 mL). A few 4 A molecular sieves were added, and the solution was warmed up to 70 C and kept for two days at this temperature. The solution was filtered and the solvent was removed under reduced pressure. The resulting yellow oily residue (crude 1) was dissolved in a mixed solvent (40 mL) of methanol and toluene (v/v = 1:3), NaBH4 (2.00 g, 52.6 mmol) was added in small portions at 0 C, then the solution was warmed up to 50 C and kept for 2 h at this temperature. The solvent was removed and the residue was treated with H2O (20 mL) and extracted with ethyl acetate (20 mL ¡Á 3) and washed with brine (20 mL). The combined organic layers were dried with anhydrous Na2SO4 and the solvent was removed under reduced pressure to give a yellow solid, which was further purified by flash column chromatography (hexane/ethyl acetate = 10:1) to give 4H3 as a yellow solid. Yield: 4.75 g (95%).

137848-29-4, The synthetic route of 137848-29-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Zhao, Ning; Chen, Liang; Ren, Wenshan; Song, Haibin; Zi, Guofu; Journal of Organometallic Chemistry; vol. 712; (2012); p. 29 – 36;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Simple exploration of 4568-71-2

4568-71-2, The synthetic route of 4568-71-2 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4568-71-2,3-Benzyl-5-(2-hydroxyethyl)-4-methylthiazol-3-ium chloride,as a common compound, the synthetic route is as follows.

Example 22 3-Ethoxycarbonyl-2-(4-fluoro-3-phenoxy-phenyl)-5-methyl-1-phenylhexane-1,4-dione STR36 142.4 g (0.4 mol) of Example 21 are heated at reflux overnight with 42.4 g (0.4 mol) of benzaldehyde, 10.8 g (0.04 mol) of 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride and 33 ml of triethylamine in 270 ml of ethanol. The solvent is removed in vacuo, and the residue is dissolved in chloroform, washed twice with 1N sulphuric acid, water and saturated bicarbonate solution and dried over sodium sulphate. After concentrating to dryness, 185.2 g of yellowish oil remain. The crude product is sufficiently pure for further processing. Rf =0.17 (petroleum ether/ethyl acetate 10:1).

4568-71-2, The synthetic route of 4568-71-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Bayer Aktiengesellschaft; US4968681; (1990); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Downstream synthetic route of 1671-87-0

The synthetic route of 1671-87-0 has been constantly updated, and we look forward to future research findings.

1671-87-0, 3,6-Di(pyridin-2-yl)-1,2,4,5-tetrazine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1671-87-0, A 10-3 M solution of compound 4 in 1:1 ethanol:H2O and a 10-2 M solution of compound 12 in ethanol were prepared separately. 50 muL of the 10-3 M solution of compound 4 and 50 muL of the 10-2 M solution of compound 12 were added to a glass vial containing 1 mL of 10% untreated rabbit reticulocyte lysate in H2O. The solution was stirred at room temperature for 1 hr. The solution was extracted with ether and CH2Cl2, dried over Na2SO4, filtered through celite, and concentrated in vacuo. The resulting residue was diluted with 100 muL of methanol and analyzed by ESI-MS and compound 13 was detected. The yield was 76% versus an internal standard.

The synthetic route of 1671-87-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; University of Delaware; US2009/23916; (2009); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Simple exploration of 10534-59-5

The synthetic route of 10534-59-5 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10534-59-5,Tetrabutylammonium acetate,as a common compound, the synthetic route is as follows.

General procedure: The solution of a receptor (~10-3 M) was titrated in NMR tube with the 0.1-0.3 M solution of arespective TBA salt. The solution of the salt contained a certain amount of the receptor to keep receptorconcentration constant during titration experiments. It was important to choose such volumes ofaliquots so that most of the data points could occur in close proximity of the inflection point of therespective titration curve; 11 to 23 data points were recorded. Such procedure allows for more precisecalculation of binding constants. A nonlinear curve fitting for the 1:1 binding model was carried outwith the HypNMR2008 Software [26-28] (Version 4.0.71) and allows the determination of the globalassociation constant. The details are given in ESI Figures S27-S65 and Tables S1-S38., 10534-59-5

The synthetic route of 10534-59-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Tyszka-Gumkowska, Agata; Pikus, Grzegorz; Jurczak, Janusz; Molecules; vol. 24; 14; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Brief introduction of 137076-54-1

137076-54-1, 137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

Example 6.1 Preparation of compounds 30a-b- General Procedure: HBTU (1 eq) and DIPEA (1.7 eq) were sequentially added to a suspension ofcompound 26 in CH2CI2 (concentration 1% w/v) and the mixture was keptunder stirring at room temperature for 30 min; phosphoethanolamine (DLPEn = 10 or DMPE n = 12) (1 eq) was then added and the mixture was maintained under stirring at room temperature for 24 h. The reactionmixture was sequentially washed with H20 (100 mL), acidified H20 (pH 4-5with HCI; 100 mL) and H20 (100 mL). The organic layer was dried(Na2S04), filtered and evaporated, and the so-obtained crude material waspurified by flash chromatography to obtain compounds 30a-b. Example 6.1a Preparation of 10-[(10R)-7-hydroxy-7-oxido-2,13-dioxo-10-[(1-oxododecyl)oxy]-6,8,12-trioxa-3-aza-7-phosphatetracos-1-yl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid tris [(1,1-dimethyl)ethyl] ester 30aReagents: Compound 26 (968 mg; 1.69 mmol); 1,2-didodecanoyl-sn-glycero-3-phosphoethanolamine (980 mg; 1.69 mmol).Compound 30a (605 mg, 0.53 mmol); Yield 32%.Analytical dataHPLC-ELSD: 40.6% (area%)Mr: 1134.48 (C57H 108N5015P) 1H-and 13C-NMR and MS are compatible with the structure.

137076-54-1, 137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BRACCO IMAGING SPA; GHIANI, Simona; MAIOCCHI, Alessandro; BRIOSCHI, Chiara; VISIGALLI, Massimo; CABELLA, Claudia; MIRAGOLI, Luigi; WO2014/37498; (2014); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Simple exploration of 1067-33-0

The synthetic route of 1067-33-0 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1067-33-0,Dibutyltin diacetate,as a common compound, the synthetic route is as follows.

[Example 11] 289 g of di-n-butyl tin diacetate and 1024 g of bis(2-ethylbutyl) carbonate were placed in a 2 L volumetric eggplant-shaped flask in a nitrogen atmosphere at atmospheric pressure, and the flask was attached to a rotary evaporator to which was connected an oil bath equipped with a temperature controller, a vacuum pump and a vacuum controller. The purge valve outlet of the rotary evaporator was connected to a line containing nitrogen gas flowing at atmospheric pressure. After replacing the inside of the system with nitrogen, the temperature of the oil bath was set to 280C, the flask was immersed in the oil bath and rotation of the rotary evaporator was started. A low boiling point component was distilled off for about 7 hours in the presence of nitrogen at atmospheric pressure with the purge valve of the rotary evaporator left open, after which the pressure in the system was gradually reduced, and residual low boiling point component was distilled off with the pressure inside the system at 76 to 10 kPa. When the low boiling point component fraction no longer appeared, the flask was removed from the oil bath and allowed to cool. 365 g of residual liquid were obtained in the flask. Based on the results of 1H- , 13C- and 119Sn-NMR analyses, the residual liquid in the flask was a solution containing 79.7% by weight of di-n-butyl-bis(2-ethylbutyloxy) tin and 7.6% by weight of tri-n-butyl-(2-ethylbutyloxy) tin. On the other hand, 888 g of low boiling point component were recovered. When analyzed by gas chromatography, the low boiling point component contained about 25.2% by weight of (2-ethylbutyl) acetate., 1067-33-0

The synthetic route of 1067-33-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Asahi Kasei Chemicals Corporation; EP2226328; (2010); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Simple exploration of 1662-01-7

The synthetic route of 1662-01-7 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: In a three-neck round bottom flask, dibenzoylmethane (0.673 g, 3 mmol)and phen (0.198 g, 1 mmol) were dissolved in hot methanol (20 mL). To the solution mixture, 3 mL o fsodium hydroxide (0.1 M) was added. The temperature of the reaction mixture was maintained at 50-60C in which then Sm(NO3)3¡¤6H2O (0.445 g, 1 mmol) in methanol (20 mL) was added dropwise with stirring for 30 min. After two hours, the reaction mixture was cooled to room temperature and the resulting precipitate was filtered using vacuum filtration, washed with distilled water and cold ethanol. The product was air dried overnight. Yield: 0.252 g, 40%., 1662-01-7

The synthetic route of 1662-01-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Saleh, Muhammad Idiris; Choo, Min Yee; Chan, Tai Wei; Razali, Mohd R; Journal of Chemical Sciences; vol. 127; 12; (2015); p. 2241 – 2249;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Brief introduction of 13910-48-0

13910-48-0 N1-Benzylpropane-1,3-diamine 83811, acatalyst-ligand compound, is more and more widely used in various fields.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13910-48-0,N1-Benzylpropane-1,3-diamine,as a common compound, the synthetic route is as follows.

c) methyl [(4Z)-4-(4-benzyl-l,4-diazepan-2-ylidene)-l-(2-chlorophenyl)-5-oxo-4,5- dihydro-lH-pyrazol-3-yl] acetate Compound of Formula (II), Scheme 1)To a solution of the above obtained methyl [4-(chloroacetyl)-l-(2-chlorophenyl)-5- hydroxy-lH-pyrazol-3-yl]acetate (Compound of Formula (V), 1.88 mmol, 1 eq.) in 3 mL of acetonitrile was added, slowly at zero degree Celsius, N-benzylpropane-l ,3-diamine (0.277 mg, 0.9 eq.). The reaction mixture was stirred at 0C for 0.5 h. The resulting solution was purified by silica plug using ethylacetate/0.1% triethylamine. The solvent was evaporated in vacuo and allowed to isolate a red solid which proved to be the pure methyl [(4Z)-4-(4- benzyl-l,4-diazepan-2-ylidene)-l-(2-chlorophenyl)-5-oxo-4,5-dihydro-lH-pyrazol-3-yl] acetate (0.530 g). Yield 71 %. MS(ESI+): 454.0., 13910-48-0

13910-48-0 N1-Benzylpropane-1,3-diamine 83811, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; GENKYOTEX SA; PAGE, Patrick; GAGGINI, Francesca; LALEU, Benoit; WO2011/36651; (2011); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Brief introduction of 10534-59-5

As the paragraph descriping shows that 10534-59-5 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10534-59-5,Tetrabutylammonium acetate,as a common compound, the synthetic route is as follows.

To a stirred solution of (25,5 ?)-6- hydroxy-A^-(lH-imidazol- l-ylacetyl)-7-oxo- l,6-diazabicyclo[3.2.1]octane-2-carbohydrazide (10.3 g, 33.4 mmol, product obtained in step 4) in dimethylformamide (70 ml) was added dimethylformamide sulfur trioxide complex (6.45 g, 42.1 mmol). The reaction mixture was stirred at 10- 15C. The progress of reaction was monitored by thin layer chromatography using mixture of chloroform and methanol (8:2) as solvent. After completion of the reaction, solution of tetrabutyl ammonium acetate (12.69 g, 42 mmol) in water (43 ml) was added to the reaction mixture under stirring. After complete conversion to tetrabutylammoinum salt, the volatiles were removed under vacuum at 40-45 C. The obtained residue was partitioned in mixture of dichloro methane and water (140 ml + 140 ml). The organic layer was dried over anhydrous sodium sulfate and distilled to get 23 g of crude product. The crude product was purified by column chromatography using 100-200 mesh silica gel using mixture of chloroform and methanol as an eluent. The pure fractions were collected and were concentrated to obtain 12 g of tetrabutyl ammonium salt of (2S,5R)-iV-(lH- imidazol- l-ylacetyl)-7-oxo-6-(sulfooxy)- l,6-diazabicyclo[3.2.1]octane-2-carbohydrazide in 54.15% yield, 10534-59-5

As the paragraph descriping shows that 10534-59-5 is playing an increasingly important role.

Reference£º
Patent; WOCKHARDT LIMITED; TADIPARTHI, Ravikumar; PATIL, Vijaykumar Jagdishwar; DEKHANE, Deepak; SHAIKH, Mohammad Usman; BIRAJDAR, Satish; DOND, Bharat; PATEL, Mahesh Vithalbhai; (100 pag.)WO2017/81615; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Analyzing the synthesis route of 109073-77-0

The synthetic route of 109073-77-0 has been constantly updated, and we look forward to future research findings.

109073-77-0, [2,2′-Bipyridine]-4,4′-diyldimethanol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Cobalt(II) tetrafluoroborate hexahydrate (156mg, 0.46mmol) was added to 4,4?-Bis(hydroxymethyl)-2,2?-bipyridine 8 (408mg, 1.89mmol) dissolved in absolute ethanol (37mL). The solution was refluxed under stirring for 24h, concentrated and dried under vacuum. The solid was dissolved in a minimum of methanol and dichloromethane was added slowly. The formed precipitate was filtrated and washed with dichloromethane, leading to a yellow solid. Yield: 95%,, 109073-77-0

The synthetic route of 109073-77-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; He; Fontmorin; Hapiot; Soutrel; Floner; Fourcade; Amrane; Geneste; Electrochimica Acta; vol. 207; (2016); p. 313 – 320;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI